Food Allergy Market

DelveInsight’s ‘Food Allergy(FA)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Food Allergy (FA), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Food Allergy (FA) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted FA symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Food Allergy (FA) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Food Allergy (FA) Disease Understanding and Treatment Algorithm

Food Allergy (FA) Overview

A Food Allergy (FA) is an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food. Food allergens are the parts of food or ingredients within food (proteins usually) recognized by immune cells. When an immune cell binds to a food allergen, a reaction occurs that causes the symptoms of food allergy (Valenta et al., 2015)


Food intolerances are adverse health effects caused by foods. They do not involve the immune system. For example, if someone is lactose intolerant, they miss the enzyme that breaks down lactose, a sugar found in milk. However, allergy refers to conditions that involve changes to one’s immune system. These immune system changes are divided into two categories: Immunoglobulin E (IgE) mediated and non–IgE-mediated.


Symptoms of a Food Allergy (FA) may range in severity from mild localized oral itching with ingestion of fresh fruits or vegetables in individuals with pollen-food allergy syndrome to life-threatening states in individuals with anaphylactic reactions to foods, such as peanut (Bird et al., 2019).


Food Allergy (FA) symptoms are most common in babies and children, but they can appear at any age. It is a significant public health problem that affects adults and children and may also be increasing in prevalence. Moreover, the diagnosis of a food allergy may be problematic, given that nonallergic food reactions, such as food intolerance, are frequently confused with food allergies (Boyce et al., 2010).


Diagnosis is complicated by the observation that detecting food-specific IgE (sensitization) does not necessarily indicate a clinical allergy. Therefore, diagnosis requires a careful medical history, laboratory studies, and, in many cases, an oral food challenge to confirm a diagnosis. Novel diagnostic methods, including ones that focus on immune responses to specific food proteins or epitopes of specific proteins, are under study (Sicherer & Sampson, 2010).


Food Allergy (FA) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Food Allergy (FA) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Food Allergy (FA) market report gives a thorough understanding of FA symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides FA symptoms of treatment algorithms and treatment guidelines for FA symptoms in the US, Europe, and Japan.

Food Allergy (FA) Epidemiology

The epidemiology division’s Food Allergy (FA) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Food Allergy (FA) epidemiology segmented as the Total Prevalent Cases of Food Allergy (FA), Prevalent cases of FA based on Etiology-specific factors, Age-specific Prevalence of Food allergy. The report includes the prevalent FA scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Food Allergy (FA) Epidemiology

The epidemiology segment also provides the Food Allergy (FA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The total 7MM prevalent cases of Food Allergy (FA) were 56,849,000 in 2020.

Food Allergy (FA) Drug Chapters 

The drug chapter segment of the Food Allergy (FA) report encloses the detailed analysis of FA marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Food Allergy (FA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Chemotherapy or immunotherapy may be warranted postoperatively, depending on cancer staging and nodal involvement. The surgical nurse practitioner, a member of the medical oncology team, can coordinate the surveillance plan of care and review laboratory results.

Products detail in the report…


Food Allergy (FA) Emerging Drugs


Ligelizumab: Novartis Pharmaceuticals

Ligelizumab (QGE031), a humanized anti-IgE antibody developed by Novartis, is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. It is also directed against Cε3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139 pM (as compared to the KD of omalizumab, ~6–8 nm) ( Balbino &. Reber, 2018).

Products detail in the report…

Food Allergy (FA) Market Outlook

The Food Allergy (FA) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Food Allergy (FA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.


This segment gives a thorough detail of Food Allergy (FA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, Food Allergy (FA) market in 7MM is expected to change in the study period 2018–2030.


Key Findings

This section includes a glimpse of the Food Allergy (FA) market in 7MM. The market size of FA in the seven major markets was found to be USD 1,091 million in 2020.


The United States Market Outlook

This section provides a total of Food Allergy (FA) market size and market size by therapies in the United States.


The United States accounts for the highest FA market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


EU-5 Countries: Market Outlook

The total Food Allergy (FA) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Food Allergy (FA) market size and market size by therapies in Japan are also mentioned.

Food Allergy (FA) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Food Allergy (FA) market uptake by drugs, patient uptake by therapies, and drug sales.


This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Food Allergy (FA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Food Allergy (FA) key players involved in developing targeted therapeutics.


Major players Ligelizumab (Novartis Pharmaceuticals), Viaskin Peanut (DBV Technologies), INP20 (InnoUp Farma S.L.) etc being assessed as potential therapies to be available in the market in the coming future.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Food Allergy (FA) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working Food Allergy (FA) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Food Allergy (FA) market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Food Allergy (FA) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Food Allergy (FA) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Food Allergy (FA) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Food Allergy (FA) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Food Allergy (FA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Food Allergy (FA) market

Report Highlights

  • In the coming years, Food Allergy (FA) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Food Allergy (FA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for FA. The launch of emerging therapies will significantly impact the Food Allergy (FA) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for FA
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Food Allergy (FA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Food allergy(FA) Pipeline Analysis
  • Food allergy(FA) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Food Allergy (FA) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Food allergy(FA) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Food Allergy (FA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Food Allergy (FA) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Food Allergy (FA) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Food Allergy (FA) market Size during the forecast period (2021–2030)?
  • At what CAGR, the Food Allergy (FA) market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Food Allergy (FA) market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Food Allergy (FA) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Food Allergy (FA)?
  • What is the historical Food Allergy (FA) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Food Allergy (FA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Food Allergy (FA)?
  • Out of all 7MM countries, which country would have the highest prevalent Food Allergy (FA) population during the forecast period (2021–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Food Allergy (FA)?
  • What are the current treatment guidelines for treating Food Allergy (FA) in the USA, Europe, and Japan?
  • What are the Food Allergy (FA) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Food Allergy (FA)?
  • How many therapies are developed by each company for the treatment of Food Allergy (FA)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Food Allergy (FA)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Food Allergy (FA) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Food Allergy (FA) and their status?
  • What are the key designations that have been granted for the emerging therapies for Food Allergy (FA)?
  • What are the global historical and forecasted markets of Food Allergy (FA)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Food Allergy (FA) market
  • To understand the future market competition in the Food Allergy (FA) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Food Allergy (FA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Food Allergy (FA) market
  • To understand the future market competition in the Food Allergy (FA) market

1. Key Insights

2. Report Introduction

3. Food Allergy (FA) Market Overview at a Glance

3.1. Market Share (%) Distribution of Food allergy in 2018

3.2. Market Share (%) Distribution of Food allergy in 2030

4. Executive Summary of Food allergy

5. Organizations contributing towards Food Allergy (FA)

6. Disease Background and Overview

6.1. Introduction

6.2. Etiology

6.3. Clinical Manifestations

6.4. Subtypes of Food Allergy

6.5. Diagnosis

7. Management and Treatment

7.1. Guidelines

7.2. Japanese Guidelines for Food allergies

7.2.1. Symptom Severity and Treatment

7.2.1.1. Grading symptom severity

7.2.1.2. Treatment based on symptom severity

7.2.1.3. Evaluation of organ-specific symptoms

7.2.2. Management of Anaphylaxis in a Health Care Setting

7.2.2.1. Confirmation of vital signs

7.2.2.2. Ensuring staff and treatment by a team

7.2.2.3. Intramuscular injection of adrenaline

7.2.2.4. Body position of the anaphylaxis patients

7.2.2.5. Administration of oxygen

7.2.2.6. Securing the intravenous infusion route and rapid rehydration

7.2.2.7. Cessation of respiration

7.2.2.8. Measurement of vital signs: Re-evaluation

7.2.3. Contraindication of adrenaline

7.3. The European Academy of Allergy and Clinical Immunology (EAACI) Guidelines

7.4. American Guidelines for the Diagnosis and Management of Food allergies

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. 7MM Total Prevalent Patient Population of Food Allergy (FA)

8.3. Assumption and Rationale

8.4. The United States

8.4.1. Prevalent cases of Food Allergy (FA) in the United States

8.4.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in the United States

8.4.3. Age-specific Prevalence of Food Allergy (FA) in the United States

8.5. EU5

8.5.1. Germany

8.5.1.1. Prevalent cases of Food Allergy (FA) in Germany

8.5.1.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Germany

8.5.1.3. Age-specific Prevalence of Food Allergy (FA) in Germany

8.5.2. France

8.5.2.1. Prevalent cases of Food Allergy (FA) in France

8.5.2.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in France

8.5.2.3. Age-specific Prevalence of Food Allergy (FA) in France

8.5.3. Italy

8.5.3.1. Prevalent cases of Food Allergy (FA) in Italy

8.5.3.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Italy

8.5.3.3. Age-specific Prevalence of Food Allergy (FA) in Italy

8.5.4. Spain

8.5.4.1. Prevalent cases of Food Allergy (FA) in Spain

8.5.4.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Spain

8.5.4.3. Age-specific Prevalence of Food allergy in Spain

8.5.5. United Kingdom

8.5.5.1. Prevalent cases of Food Allergy (FA) in the United Kingdom

8.5.5.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in the United Kingdom

8.5.5.3. Age-specific Prevalence of Food Allergy (FA) in the United Kingdom

8.6. Japan

8.6.1. Prevalent cases of Food Allergy (FA) in Japan

8.6.2. Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Japan

8.6.3. Age-specific Prevalence of Food Allergy (FA) in Japan

9. Patient Journey

10. Case Reports

11. Marketed Therapies

11.1. Palforzia: Aimmune Therapeutics, Inc.

11.1.1. Drug Description

11.1.2. Other Development Information

11.1.3. Safety and Efficacy

11.1.4. Product Profile

12. Emerging Therapies

12.1. Ligelizumab: Novartis Pharmaceuticals

12.1.1. Drug Descriptions

12.1.2. Clinical Development

12.1.3. Clinical Trials Information

12.1.4. Product Profile

12.2. Viaskin Peanut: DBV Technologies

12.2.1. Drug Descriptions

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Product Profile

12.3. INP20: InnoUp Farma S.L.

12.3.1. Drug Descriptions

12.3.2. Clinical Development

12.3.3. Clinical Trials Information

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. CNP-201: COUR Pharmaceutical Development Company Inc.

12.4.1. Drug Descriptions

12.4.2. Clinical Development

12.4.3. Clinical Trials Information

12.4.4. Product Profile

12.5. VE416: Vedanta Biosciences, Inc.

12.5.1. Drug Descriptions

12.5.2. Clinical Development

12.5.3. Clinical Trials Information

12.5.4. Product Profile

12.6. AR201: Aimmune Therapeutics, Inc.

12.6.1. Drug Descriptions

12.6.2. Other Developmental Activities

12.6.3. Clinical Development

12.6.4. Clinical Trials Information

12.6.5. Safety and Efficacy

12.6.6. Product Profile

12.7. Dupilumab: Regeneron Pharmaceuticals

12.7.1. Drug Descriptions

12.7.2. Other Developmental Activities

12.7.3. Clinical Development

12.7.4. Clinical Trials Information

12.7.5. Product Profile

12.8. Omalizumab: Genentech, Inc. /Novartis Pharmaceuticals

12.8.1. Drug Descriptions

12.8.2. Other Development Information

12.8.3. Clinical Development

12.8.4. Clinical Trials Information

12.8.5. Safety and Efficacy

12.8.6. Product Profile

12.9. CA002: Camallergy

12.9.1. Drug Description

12.9.2. Other development activity

12.9.3. Clinical Development

12.9.4. Clinical Trials Information

12.9.5. Safety and Efficacy

12.9.6. Product profile

13. Food allergy: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Food allergy in 7MM

13.3. Market Size of Food allergy by Therapies

14. Market Outlook

14.1. United States Market Size

14.1.1. Total Market Size of Food Allergy (FA) in the United States

14.1.2. Market Size of Food Allergy (FA) by Therapies in the United States

14.2. EU-5 Market Size

14.2.1. Germany

14.2.1.1. Total Market size of Food Allergy (FA) in Germany

14.2.1.2. Market Size of Food Allergy (FA) by Therapies in Germany

14.2.2. France

14.2.2.1. Total Market size of Food Allergy (FA) in France

14.2.2.2. Market Size of Food Allergy (FA) by Therapies in France

14.2.3. Italy

14.2.3.1. Total Market size of Food Allergy (FA) in Italy

14.2.3.2. Market Size of Food Allergy (FA) by Therapies in Italy

14.2.4. Spain

14.2.4.1. Total Market size of Food Allergy (FA) in Spain

14.2.4.2. Market Size of Food Allergy (FA) by Therapies in Spain

14.2.5. United Kingdom

14.2.5.1. Total Market size of Food Allergy (FA) in United Kindgom

14.2.5.2. Market Size of Food Allergy (FA) by Therapies in United Kingdom

14.3. Japan

14.3.1. Total Market size of Food Allergy (FA) in Japan

14.3.2. Market Size of Food Allergy (FA) by Therapies in Japan

15. KOL Views

16. Unmet Needs

17. Market Drivers

18. Market Barriers

19. SWOT Analysis

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Food Allergy (FA), Market, Epidemiology, and Key Events (2018–2030)

Table 2: Organizations contributing towards Food Allergies

Table 3: Classification of Food Allergies

Table 4: Total Prevalent Patient Population of Food Allergy (FA) in 7MM (2018–2030)

Table 5: Prevalent cases of Food Allergy (FA) in the United States (2018–2030)

Table 6: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factor in the United States in (2018–2030)

Table 7: Age-specific Prevalence of Food Allergy (FA) in the United States (2018–2030)

Table 8: Prevalent cases of Food Allergy (FA) in Germany (2018–2030)

Table 9: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factor in Germany (2018–2030)

Table 10: Age-specific Prevalence of Food Allergy (FA) in Germany (2018–2030)

Table 11: Prevalent cases of Food Allergy (FA) in France (2018–2030)

Table 12: Prevalent Cases of Food Allergy (FA) based on Risk Factors in France (2018–2030)

Table 13: Age-specific Prevalence of Food Allergy (FA) in France (2018–2030)

Table 14: Prevalent cases of Food Allergy (FA) in Italy (2018–2030)

Table 15: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Italy (2018–2030)

Table 16: Age-specific Prevalence of Food Allergy (FA) in Italy (2018–2030)

Table 17: Prevalent cases of Food Allergy (FA) in Spain (2018–2030)

Table 18: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Spain (2018–2030)

Table 19: Gender-specific Prevalence of Food Allergy (FA) in Spain (2018–2030)

Table 20: Prevalent cases of Food Allergy (FA) in United Kingdom (2018–2030)

Table 21: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in United Kingdom in (2018–2030)

Table 22: Age-specific Prevalence of Food Allergy (FA) in the United Kingdom (2018–2030)

Table 23: Prevalent cases of Food Allergy (FA) in Japan (2018–2030)

Table 24: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Japan (2018–2030)

Table 25: Age-specific Prevalence of Food Allergy (FA) in Japan (2018–2030)

Table 26: Ligelizumab (QGE031), Clinical Trial Description, 2021

Table 27: Viaskin Peanut, Clinical Trial Description, 2021

Table 28: INP20, Clinical Trial Description, 2021

Table 29: CNP-201, Clinical Trial Description, 2021

Table 30: VE416, Clinical Trial Description, 2021

Table 31: AR201, Clinical Trial Description, 2021

Table 32: Dupilumab, Clinical Trial Description, 2021

Table 33: Omalizumab, Clinical Trial Description, 2021

Table 34: CA002, Clinical Trial Description, 2021

Table 35: 7 Major Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 36: 7 Major Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 37: United States Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 38: United States Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 39: Germany Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 40: Germany Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 41: France Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 42: France Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 43: Italy Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 44: Italy Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 45: Spain Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 46: Spain Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 47: United Kingdom Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 48: United Kingdom Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Table 49: Japan Market Size of Food Allergy (FA) in USD Million (2018–2030)

Table 50: Japan Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Immune Cell Function

Figure 2: Total Prevalent Population of Food Allergy (FA) in 7MM (2018–2030)

Figure 3: Prevalent cases of Food Allergy (FA) in the United States (2018–2030)

Figure 4: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factor in the United States (2018–2030)

Figure 5: Age-specific Prevalence of Food Allergy (FA) in the United States (2018–2030)

Figure 6: Prevalent cases of Food Allergy (FA) in Germany (2018–2030)

Figure 7: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factor in Germany (2018–2030)

Figure 8: Age-specific Prevalence of Food Allergy (FA) in Germany (2018–2030)

Figure 9: Prevalent cases of Food Allergy (FA) in France (2018–2030)

Figure 10: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factor in France (2018–2030)

Figure 11: Age-specific Prevalence of Food Allergy (FA) in France (2018–2030)

Figure 12: Prevalent cases of Food Allergy (FA) in Italy (2018–2030)

Figure 13: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Italy (2018–2030)

Figure 14: Age-specific Prevalence of Food Allergy (FA) in Italy (2018–2030)

Figure 15: Prevalent cases of Food Allergy (FA) in Spain (2018–2030)

Figure 16: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Spain (2018–2030)

Figure 17: Age-specific Prevalence of Food Allergy (FA) in Spain (2018–2030)

Figure 18: Prevalent cases of Food Allergy (FA) in United Kingdom (2018–2030)

Figure 19: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in United Kingdom (2018–2030)

Figure 20: Age-specific Prevalence of Food Allergy (FA) in the United Kingdom (2018–2030)

Figure 21: Prevalent cases of Food Allergy (FA) in Japan (2018–2030)

Figure 22: Prevalent Cases of Food Allergy (FA) based on Etiology-specific factors in Japan (2018–2030)

Figure 23: Age-specific Prevalence of Food Allergy (FA) in Japan (2018–2030)

Figure 24: 7 Major Market Size of Food Allergy (FA) in USD Million (2018–2030)

Figure 25: 7 Major Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Figure 26: Market Size of Food Allergy (FA) in the United States, USD Million (2018–2030)

Figure 27: The United States Market Size of Food Allergy (FA) by Therapies in USD Million

Figure 28: Market Size of Food Allergy (FA) in the Germany, USD Million (2018–2030)

Figure 29: The Germany Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Figure 30: Market Size of Food Allergy (FA) in the France, USD Million (2018–2030)

Figure 31: The France Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Figure 32: Market Size of Food Allergy (FA) in the Italy, USD Million (2018–2030)

Figure 33: The Italy Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Figure 34: Market Size of Food Allergy (FA) in the Spain, USD Million (2018–2030)

Figure 35: The Spain Market Size of Food Allergy (FA) by Therapies in USD Million

Figure 36: Market Size of Food Allergy (FA) in the United Kingdom, USD Million (2018–2030)

Figure 37: The United Kingdom Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Figure 38: Market Size of Food Allergy (FA) in the Japan, USD Million (2018–2030)

Figure 39: The Japan Market Size of Food Allergy (FA) by Therapies in USD Million (2018–2030)

Aimmune Therapeutics, Inc.

Novartis Pharmaceuticals

DBV Technologies

InnoUp Farma S.L.

COUR Pharmaceutical Development Company Inc.

Vedanta Biosciences, Inc.

Aimmune Therapeutics, Inc.

Regeneron Pharmaceuticals

Genentech, Inc.

Camallergy

Novartis Pharmaceuticals

  • Tags:
  • Food Allergy (FA) market
  • Food Allergy (FA) market size
  • Food Allergy (FA) market share
  • Food Allergy (FA) market size and...
  • Food Allergy (FA) market research...
  • Food Allergy (FA) market trends
  • Food Allergy (FA) pipeline
  • Food Allergy (FA) drugs market
  • Food Allergy (FA) epidemiology
  • Food Allergy (FA) market forecast

Forward to Friend

Need A Quote